Introduction

Travelling is an integral part of modern life, and enjoyed by most people. Unfortunately, travelling has risks associated with it, which are not always tolerated by all travellers. Travelling has an impact on public health, as travellers are not only at risk of being exposed to various diseases and other adverse health outcomes inside and outside their home country, they can also import non-endemic diseases into their home country or export non-endemic diseases to the destination country.

Statistics show that travelling, especially to international destinations, is on the increase, subsequently exposing more people to travel-associated risks. The World Tourism Organisation estimated 1.2 billion world-wide international tourist arrivals in 2015, which was a 4% increase from 2013. Similarly, an increase in travelling to other destinations such as Asia and Africa, places more travellers at risk for various travel-related conditions, and other tropical or vaccine-preventable infections. Data on the actual risk for travellers are limited, as it is difficult to obtain an accurate numerator (number of cases of disease among travellers) and denominator (number of travellers overall or travellers to a specific destination who are susceptible to infection and illness). Risks associated with travelling include travel-related infections which, in most cases, can be prevented by vaccines, such as hepatitis, meningitis, yellow fever, and rabies. Other infections such as malaria, can be prevented by chemoprophylaxis, combined with protective measures against mosquito bites.

The practice of travel medicine and travellers’ health is a continuum and includes the pre-travel health and risk assessment, contingency planning during travel and taking care of the traveller after travel (see Figure 1). A pre-travel risk assessment is important to identify any hazards and risks, for which vaccination, prophylaxis or any other intervention could be prescribed. During travel, precautionary measures should be followed to limit exposure to risks. On return, prophylactic medication must be completed, and if not well, travellers should immediately seek medical advice and inform the medical practitioner of recent travel. Travellers should be cognisant of the fact that no intervention provides 100% protection. Morbidity and mortality from diseases such as malaria, which may still occur post-travel, can be reduced significantly through early identification and management post-travel. Similarly, the risk to the traveller’s community from a disease such as dengue fever, can be reduced through early recognition and management.

Pre-travel preparation

As part of travel preparation and planning, travellers are advised to have a pre-travel risk assessment done, at least four to eight weeks before travelling. This can be done by a travel medicine provider at a travel clinic or through consultation with a healthcare provider (medical practitioner, nurse, pharmacist).

The purpose of a pre-travel risk assessment is to identify possible risks and then aim to modify those risks with an intervention. Interventions include immunisation, prophylactic medication and taking the necessary clothing, equipment or devices (e.g. water filter or mosquito net) according to the health conditions and climate of the travel destination. The past medical history and current health status of the traveller should also be evaluated. Figure 1 illustrates the factors to consider when doing a pre-travel risk assessment, as part of the continuum of travel medicine.
Measures against infectious diseases related to travel

**Immunisation**

As part of the pre-travel risk assessment, immunisation which could protect the traveller against infectious diseases, should be considered. The benefits of vaccination extend beyond the travel period, and in many cases lifelong immunity is achieved. There is, however, not a vaccine available for every disease, neither does immunisation always offer 100% protection, nor lifelong protection. Vaccination, though will greatly reduce the chances of acquiring the disease and in many cases offer an extremely high level of protection. Conversely, it is important for travellers to not only rely on immunisation for protection, but also to use other strategies and protective measures to safeguard their health (see Figure 2).

The Centres for Disease Control and Prevention (CDC), recommend that all travellers should be up-to-date with routine vaccines before international travel, regardless of destination. One should therefore verify whether the traveller is immune to diseases (e.g. measles) which are covered by routine vaccination, and whether the travellers’ routine vaccination, according to the South African Expanded Programme on Immunisation (EPI) schedule, is up-to-date.

There are many vaccinations available for an extensive list of travel-related infectious diseases. The itinerary of the traveller must therefore be reviewed to determine the need for specific vaccines based on the travel destination or purpose of the travel, particularly when travelling to unusual destinations. The most commonly recommended vaccines for most destinations, according to risk of infection for the traveller, include vaccines against influenza, measles, hepatitis A and B, and pneumococcal disease. The World Health Organization (WHO) International Travel and Health website provides useful information for travellers about the main infectious disease threats, their geographical distribution and precautionary measures, including information on vaccine-preventable diseases.

Mandatory vaccinations to protect against diseases such as yellow fever, meningococcal disease and polio are required for specific travel destinations. Requirements of different countries are subject to change at any time. Travellers therefore need to verify the specific vaccination requirements with the relevant consulate or embassy of the country they are travelling to. The latest updates on mandatory vaccination, can be found on the WHO International Travel and Health website.
Malaria

Malaria is a life-threatening disease, and transmitted to humans by the bite of an infected female Anopheles mosquito. The two most common species of the Plasmodium parasite that cause malaria are Plasmodium falciparum and Plasmodium vivax. Sub-Saharan Africa has the largest morbidity and mortality associated with malaria. Malaria is characterised by fever and influenza-like symptoms, including chills, headache, myalgia, and malaise; which can occur at intervals. Mosquitoes breed in stagnant water and thrive in tropical climates, hence travellers in these endemic areas should take great care to prevent being bitten by mosquitoes. Malaria diagnostic tests are available in most health services in the endemic regions and in reference centres for infectious diseases in teaching hospitals.

With malaria prevention, measures are taken against both the mosquito vectors and against the malaria parasite. Prevention measures, commonly referred to as the ‘A,B,C’ of malaria prevention, include vector control programmes by government health authorities, personal protection measures against mosquito bites and the use of chemoprophylaxis:

A = Awareness of malaria risk
B = Being aware of mosquito bites and peak biting times
C = Taking appropriate Chemoprophylaxis
D = Early Detection of infection
E = Getting Effective treatment

The WHO provides specific recommendations on malaria prevention based on the risk of contracting malaria, the prevailing species of malaria parasites in the area, the level and spread of drug resistance reported from the country, and the possible risk of serious side-effects resulting from the use of the various prophylactic drugs. Prevention against Plasmodium falciparum takes priority where both species occur, and unless the malaria risk is defined as due “exclusively” to a certain species, travellers may be at risk of any of the parasite species, including mixed infections. Current chloroquine and sulfadoxine-pyrimethamine are neither used in the prevention nor the treatment of falciparum malaria, as Plasmodium falciparum resistance is nearly universal. South Africa has a risk of Plasmodium falciparum malaria, in combination with reported chloroquine and sulfadoxine–pyrimethamine resistance, throughout the year in low-altitude areas of Mpumalanga Province (including the Kruger National Park), Limpopo Province and north-eastern KwaZulu-Natal. The risk is highest from October to May inclusive. Mosquito bite prevention plus the following chemoprophylaxis options are recommended, and need to be tailored to the individual traveller (i.e. children and pregnancy/lactation):

- **Mefloquine** is the prophylactic agent of choice to prevent infection from Plasmodium falciparum malaria because of resistance to chloroquine. Mefloquine should be initiated one to two weeks prior to entering an endemic area and continued as a once weekly dose for up to four weeks after the last possible exposure. Mefloquine is generally well tolerated by children and can be used for children over 3 months of age or with a weight above 5 kg. It is recommended for all trimesters of pregnancy, should travel be necessary. In general, mefloquine should be avoided in patients with mental health problems, considering its potential for neuropsychiatric side-effects.

- **Doxycycline** for malaria prophylaxis should be started 24–48 hours before entering a malaria area and continued thereafter for up to four weeks after exposure. Doxycycline is taken on a daily basis for an extended period of time, compliance should be reiterated. Doxycycline can only be used in children from the age of eight years and is contraindicated in pregnancy.

- **Atovaquone/proguanil** is a combination drug and shows the most promising safety profile compared to the other agents. Prophylactic treatment should be started one to two days before entering the malaria area, and taken daily for up to seven days after the last possible exposure. Paediatric tablets can be given to children > 11 kg. Doxycycline and atovaquone/proguanil are contraindicated in pregnancy.

**Travel-associated sexually transmitted infections**

Sexually transmitted infections (STIs) are diseases acquired through having unprotected sexual intercourse with infected persons. One risk factor for contracting STIs is considered to be travel because it disturbs individuals’ usual sexual practices through physical separation of partners and removal of inhibitions that might hinder sexual freedom.

A broad range of STIs can be acquired. Most STIs are asymptomatic, making them difficult to control. Early detection and treatment are therefore very important. The most common STIs are unspecified urethritis, gonorrhoea, syphilis, chlamydia, genital ulcers, chancroid, acute HIV infection, acute pelvic inflammatory disease, epididymitis, cervicitis, balanitis, and unspecified STIs. Prevention is the best way to decrease the morbidity and mortality associated with STIs and consistent and proper use of latex condoms during sexual activity is highly recommended. Evaluation, management, and follow-up of STIs should be based on standard treatment guidelines and per individual case.

**Patient education and travel advice**

Considering the fact that immunisation does not fully protect all vaccinated individuals, vaccinated travellers should always take extra precautionary measures to ensure an infection-free travel. Figure 2 illustrates some of the initiatives travellers can take to minimise the risk of infections.
**Common conditions related to travel**

**Travellers’ diarrhoea**

Travellers’ diarrhoea remains the most common medical problem encountered by travellers. It is a clinical syndrome associated with contaminated food or water that occurs during or shortly after travel, and is defined as three or more loose or liquid stools per day, or more frequently than is normal for the individual. Traditionally, *Escherichia coli* has been considered the major causative pathogen for travellers’ diarrhoea. Risk of travellers’ diarrhoea should be reviewed and prophylaxis offered if indicated. In most international travellers it is a self-limiting illness. The duration of travellers’ diarrhoea can be shortened with antibiotic treatment, of which fluoroquinolones e.g. levofloxacin, ciprofloxacin are currently most effective. Azithromycin is considered the best alternative treatment for travellers’ diarrhoea, and the drug of choice in children. Oral rehydration solution should be used to treat dehydration.

**Altitude illness**

Altitude illness may occur in individuals travelling to high altitude, usually above 2 500 metres. This happens when ascending too rapidly to high altitude, and the body is unable to adjust to the reduced oxygen levels. If sensible precautionary measures are taken, i.e. gradual ascent with regular rest days, most trips exposed to high altitude can be enjoyed safely.

Conditions that are contraindicated for travel to high altitude include unstable angina, pulmonary hypertension, severe chronic obstructive pulmonary disease (COPD) and sickle-cell anaemia. Altitude illness can present as acute mountain sickness (AMS) (headache, loss of appetite, nausea, vomiting, dizziness, sleep disturbance, fatigue and weakness), high altitude cerebral oedema (HACE) (confusion, altered consciousness and incoordination) and high altitude pulmonary oedema (HAPE) (increasing breathlessness, breathlessness lying flat, cough (initially dry then wet), chest tightness and blood tinged sputum). When illness is severe, these conditions are life-threatening and require urgent medical attention.

If sensible precautionary measures are taken, i.e. gradual ascent with regular rest days, most trips exposed to high altitude can be enjoyed safely. Preventative medication is not necessary for low risk situations and may be considered in addition to gradual ascent in moderate or high risk situations, however, it is not a substitute for gradual ascent.

**Motion sickness**

Motion sickness is attributed to physiological responses of the body to motion by air, sea, train or car. Common symptoms of
motion sickness include nausea, vomiting, increased salivation, warmth, dizziness, sweating, malaise, pallor, hyperventilation, feeling cold and clammy. Risk factors for motion sickness include age, i.e. children 2–12 years, females i.e. pregnant, menstruating, or on hormone treatment, migraines, certain prescription medicines and environmental factors such as the type of motion and the body position. Non-pharmacological prevention strategies for motion sickness include the following:

- Position to reduce motion or motion perception e.g. driving a vehicle instead of riding in it, sitting in the front seat of a car or bus, or sitting over the wing of an aircraft.
- Be aware of and avoid situations that would trigger symptoms.
- Reduce sensory input by lying prone, shutting eyes, or looking at the horizon.
- Maintain hydration by drinking water, eating small meals frequently, and limiting alcoholic and caffeinated beverages.
- Adding distractions e.g. listen to music, use aromatherapy scents such as mint or lavender.
- Flavoured lozenges, specifically ginger-flavoured, which may hasten gastric emptying and function as distractions.
- Use of acupressure or magnets, although scientific data on its efficacy is equivocal.
- Antihistamines cinnarizine, promethazine and cyclizine are frequently used as prophylaxis for motion sickness, but cause drowsiness as a side-effect. Non-sedating antihistamines are also used for motion sickness, however, they appear to be less effective. Other drugs used for motion sickness are scopolamine (hyoscine, most commonly administered as a transdermal patch applied every 72 hours), antidopaminergic drugs (such as prochlorperazine), metoclopramide, sympathomimetics, and benzodiazepines. Travellers should understand the risks and benefits of using antihistamines to prevent motion sickness and should consider trying the medication before travel to determine what effect it might have on them.

Jet lag

Jet lag is a temporary sleep disorder that occurs in air travellers who rapidly cross three, or more, time zones during their flight i.e. when flying east to west or west to east. It happens subsequent to the slow adjustment of the “body clock”, and the approximate 24 hour (circadian) rhythms it controls, to the time at the destination. The daily rhythms and internal drive for sleep and wakefulness are subsequently out of synchronisation. Jet-lagged travellers may experience poor sleep, poor performance in physical and mental tasks, negative subjective changes (e.g. fatigue, headache, irritability, stress, inability to concentrate, and depression), and gastrointestinal upsets and lack of interest in meals. Symptoms of jet lag gradually wear off as the body adapts to the new time zone. Not all travellers react in the same way to time zone changes, hence, individuals should determine how their own bodies respond and develop their own coping strategy accordingly. Jet lag cannot be prevented but travellers can take a number of steps before, during and after their flight, to reduce its effects (see Figure 3).

Specific travel needs and risks

Travel-related health risks are greater for certain groups of travellers, including pregnant women, infants and young children,
the elderly, immunocompromised people and those who have pre-existing problems or a chronic illness. It is very important that these travellers consult for a pre-travel risk assessment to adequately plan their trip considering their special needs.

Pregnancy

Most pregnant women are able to travel safely, with proper pre-travel considerations and preparation. Pregnant travellers should pack a travel health kit to cater for their individual needs, including, for example, all prescription medicines, prenatal vitamins, antiemetics, antacids.

The majority of vaccines are safe in pregnancy, but the patient should consult with a HCP before traveling. Hence, in specific cases such as travelling to an endemic malaria area, the pregnant traveller should consider the risks of neither herself nor the baby being protected against a specific disease, and whether the trip could be postponed until after the birth. Travelling to, and staying at destinations of high altitudes (over 3 000 m) or to very remote areas is not advisable during pregnancy. Pregnant travellers should also take cognisance of the fact that currently there is no vaccine or medicine to prevent Zika virus, which is of particular concern to pregnant women due to its link to birth defects.

Infants and geriatrics

Infants and small children are negatively affected by the changes in cabin air pressure during flights. Air travel is therefore contraindicated for infants < 48 hours old. Infants and small children are furthermore sensitive to sudden changes in altitude as well as ultraviolet radiation. In terms of vaccination and malaria prophylaxis, special needs and precautionary measures must be observed. Compared to adults, infants and small children become dehydrated more easily, especially when there is inadequate fluid intake or loss of fluid due to vomiting and/or diarrhoea.

Almost all factors contributing to travel risks are amplified in older adults, because of the decline in physiological functions with age, making them more vulnerable to most travel-related hazards. Older adults often suffer from chronic diseases, which could be a major risk factor for them, especially when exacerbated by other factors. They are also at higher risk for adverse events, as they are often more severely affected by jet lag and could be confused, even in cases where mild cognitive impairment is present. Due to these increased risks in the elderly, pre-travel planning and risk-assessment, is of utmost importance. Of special concern is the risk of venous thromboembolism, which is increased by any form of travel.

Immunocompromised travellers

The immune status of the immunocompromised traveller is of particular importance in terms of immunisation. Overall considerations for vaccine recommendations, are the same as for other travellers. Cognisance should be taken of the fact that the immune response to vaccination may be less and live vaccines may give rise to disease. In addition, the risk of severe illness or death from a vaccine-preventable disease must be weighed against potential adverse events from administering a live vaccine to an immunocompromised patient. Should the traveller not be able to tolerate recommended immunisations or prophylaxis, changing the planned itinerary or activities, or deferring the trip should be considered.

Chronic illnesses

Travelling for people with chronic illnesses can be stressful due to the physical demands of travelling. Adequate travel preparation is therefore important, especially in terms of appropriate immunisation, chronic medicines and any treatment or precautionary measures required. Patients should consult with their medical practitioner at least four to six weeks before their trip to ensure adequate time to respond to immunisation, try any required prophylactic medicines required and ensure that their chronic illness is well controlled. A summary of considerations for travellers with special medical conditions is shown in Table I.

Patients with chronic illness are advised to carry an official letter from their medical practitioner, certifying their existing medical condition/s, prescribed medication (including generic names), and any equipment required to manage their condition. If travelling by air or boat cruise, all medicines and medical supplies e.g. ostomy bags, must be packed in carry-on luggage. Keep all items in their original containers and carry a copy of the prescription. It is also advisable that travellers with chronic illnesses carry their medical information on his/her person e.g. medical alert bracelet. Travellers with chronic illnesses should ensure that they have sufficient quantities of medicines for the entire trip, plus an additional supply in case of unexpected delays. It is important to note that medicines should be taken based on elapsed time and not the time of day. Hence, scheduling when to take medicines during and after crossing time zones, should be considered and planned for.

Travellers taking chronic medication should be educated regarding possible drug interactions between their medicines and vaccines or any other medication prescribed for self-treatment e.g. travellers’ diarrhoea, malaria prophylaxis. They should take a medical kit with them, ensure that they keep well-hydrated during travelling, wear loose-fitting clothing and walk and stretch at regular intervals during long-distance travel.

Venous thromboembolism and travel

Venous thromboembolism (VTE) refers to the combination of deep vein thrombosis (DVT) and pulmonary embolism (PE). The underlying pathophysiological process seems to involve venous stasis, with resultant coagulation and thrombus formation. Should a venous thrombus (or a portion of it) become dislodged from a vessel wall in the lower extremity, for example, the resultant embolus will travel through the venous blood circulation to reach the inferior vena cava, the right atrium and right ventricle, the pulmonary artery, and will ultimately become lodged in one of the smaller arteries of the lung, resulting in PE.
Table I. Considerations for travellers with special medical conditions

<table>
<thead>
<tr>
<th>Condition</th>
<th>General considerations</th>
</tr>
</thead>
</table>
| **Cancer**                       | • Emphasise food and water precautions  
• Plan for self-management of dehydration  
• Take precaution for DVT  
• Supplemental oxygen  
• Wear loose-fitting clothing to prevent worsening of lymphoedema  
• Check for medication restrictions in destination country, especially in the case of scheduled medicines for pain control |
| **Cardiovascular diseases**      | • Plan for self-management of dehydration and volume overload; may include adjusting medication  
• Supplemental oxygen  
• Take a copy of recent ECG with  
• Take information card for pacemaker or other implanted devices  
• Take precautions for DVT  
• Have sublingual nitroglycerine available in carry-on bag  
• Mefloquine is not recommended in cardiac conduction abnormalities, particularly ventricular arrhythmias  
• Self-monitoring and management of INR should be tailored to the individual patient needs by the medical practitioner |
| **Pulmonary diseases**           | • Supplemental oxygen  
• Arrange with airline to have other equipment on plane (e.g. nebuliser)  
• Plan for self-management of exacerbations (including COPD, asthma)  
• Take precautions for DVT  
• Consider carrying a short course of antibiotics and corticosteroids for exacerbations, as appropriate and prescribed by medical practitioner  
• Consider having an inhaler available in carry-on luggage, even if not routinely used |
| **Gastrointestinal diseases**    | • Emphasise food and water precautions  
• Consider prophylactic antibiotic for travellers’ diarrhoea, as prescribed by medical practitioner  
• Avoiding undercooked seafood, if cirrhosis, or heavy alcohol use  
• May experience increased colostomy output during air travel  
• Proton-pump inhibitors and H₂ blockers may increase susceptibility to travellers’ diarrhoea  
• Use mefloquine with caution in any chronic liver disease |
| **Renal failure and chronic renal insufficiency** | • Emphasise food and water precautions  
• Dehydration can worsen renal function; plan for self-management  
• Arrange dialysis abroad, if needed  
• Adjust medication for CrCl  
• Know HIV, hepatitis C, and hepatitis B status  
• Atovaquone-proguanil contraindicated when CrCl < 30 mL/min |
| **Diabetes mellitus**            | • Plan for self-management of dehydration, diabetic foot, pressure sores  
• Insulin adjustments  
• Check blood glucose during air travel at intervals of 4–6-hours  
• Discuss changes in insulin regimen or oral agent with diabetes specialist  
• Provide medical practitioner’s letter certifying the need for all equipment, including syringes, glucose meter, and supplies  
• Keep insulin and all glucose meter supplies in carry-on luggage  
• Bring food and supplies needed to manage hypoglycaemia during travel  
• Check feet daily for pressure sores |
| **Severe allergic reactions**     | • Plan for managing allergic reaction while traveling and consider bringing a short course of corticosteroids for possible allergic reactions  
• Should always carry injectable adrenaline and antihistamines on person  
• Observe peanut allergies – policies in place by many airlines |
| **Mental health conditions**     | • Check customs regulations for prohibited medication. Carry medication in original containers, with a letter from the prescribing physician  
• Determine availability of culturally compatible mental health treatment in destination country for long-term travellers  
• For psychotropic medication refills, check with country’s embassy and reputable in-country pharmacy or healthcare provider  
• Investigate availability of laboratory facilities for measuring drug levels prior to travel. High ambient temperatures and increased sweating could lead to lithium toxicity, even on the same dose  
• Mefloquine for malaria chemoprophylaxis is not recommended, due to potential neuropsychiatric side-effects  
• Currently sober patients with substance use disorders should consider seeking out Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) meetings, depending upon the length of stay and stability of their sobriety  
• Consider travel health and medical evacuation insurance that does not exclude psychiatric evacuations for emergencies when abroad |

DVT, deep vein thrombosis; INR, international normalised ratio; COPD, chronic obstructive pulmonary disease; CrCl, creatinine clearance.
As the name implies, the deep veins of the lower extremities constitute the most common sites of DVT, and there is a significant risk of acute PE secondary to such venous thrombi (i.e. roughly 50% in the case of DVT in the proximal lower extremity, and about 25% in the case of the distal lower extremities). Severe PE may very well prove to be fatal. A DVT could, however, develop in the upper extremity as well.21

Evidence has shown that there is a definite association between long-haul flights, especially when they are more than eight hours in duration, and venous thromboembolism (VTE). Interestingly enough the risk for business class travellers is similar to that of travellers in the economy class cabin. However, the risk is greater for passengers who occupy the non-aisle seats. This is due to the fact that 75% of air-travel-associated episodes of VTE have been linked to immobility during long-distance flights. Similar increased risk of VTE is seen with other modes of travel, such as car, bus, train, also suggesting that an increased risk of VTE is caused by prolonged immobility rather than cabin environment:1

Conversely, the overall risk of developing air-travel-related VTE remains very low, but it has still been shown to be significantly higher than the same risk associated with the healthy, non-flying population. It could be said that an average long-haul flight of 12 hours in duration, with 400 passengers on board, will result in a 0.2% incidence rate of symptomatic VTE.21

Risk factors for VTE, including air travel

Travel-related VTE events are in most cases associated with pre-existing risk factors. Generally speaking the risk factors associated with VTE may be classified as either being inherited (genetic) or acquired (environmental), with the majority of VTE-associated events being linked to a combination of the two. It should also be noted that these risk factors have an additive effect on an individual’s propensity for developing a VTE. Various genetic factors may predispose an individual to a state of so-called hypercoagulability.21

Amongst the list of acquired risk factors, the following are especially important in the community (i.e. including regular air travellers) setting:1,21,24:

Age and gender-related risk factors:

- Advancing age, from 40 years onwards
- Women’s health-related risks, which include the use of oral contraceptives and hormone-replacement therapy (HRT), as well as hypercoagulability of pregnancy and the puerperium
- The male gender
- Frailty and immobility

Risk factors associated with medical illness:

- ‘Lifestyle diseases’ such as hypertension, diabetes mellitus and dyslipidaemia
- Stroke with paralysis or paresis, acute medical illness (including COPD, congestive cardiac failure and pneumonia), antiphospholipid syndrome, nephrotic syndrome and inflammatory bowel disease
- Patients with cardiac pacemakers
- Ambulatory patients with indwelling central venous catheters
- Active cancer and certain cancer chemotherapeutic agents
- Varicose veins and prior episodes of VTE
- Conditions that result in venous insufficiency

Surgical risk factors:

- Recent trauma resulting in compression of the veins or immobilisation, including plaster cast immobilisation
- Major surgery, especially the bigger orthopaedic procedures, such as hip and knee replacement surgery, and the surgical repair of hip fractures

Lifestyle-related risk factors:

- Smoking
- Obesity, especially when the body mass index (BMI) exceeds 30 kg/m²
- Conditions or circumstances that may result in prolonged immobility and venous stasis, such as long-distance travel (especially air travel), or being bedridden for more than three consecutive days

Additional risk factors for air travellers

The two major risk factors to consider are flight duration and the person’s height. Long-haul flights carry a greater risk due to the increased periods of immobility, especially single long-haul flights that last eight to ten hours or more. However, multiple long-haul flights of at least four hours in duration, or frequent flights of any duration that occur in short succession of one another, carry an increased risk for VTE as well. In terms of body height, persons who are at an increased risk are those who are shorter than 1.65 m, or taller than 1.85 m in height.21 This could be explained by the fact that airplane seats cannot be adjusted to a person’s height. Shorter people may therefore experience seat-edge pressure to the popliteal area while taller people may have less leg room.1

Furthermore, risk factors such as prolonged immobility, together with dehydration (with a resultant increase in blood viscosity) and hypobaric hypoxia (due to the pressurised passenger cabin) all increase the risk of VTE associated with air travel in patients who already have one or more of the underlying risk factors for VTE prior to their flight.15

VTE prophylaxis for air travellers

VTE associated with passenger air travel is an emerging public health concern, but there still seems to be a lack of sufficient evidence in terms of both definite causality and effective prophylactic measures. Yet, a few basic principles, based on current knowledge in this field, may be proposed for the prevention of VTE during air travel, as illustrated in Figure 4,1,21,23

Anticoagulant prophylaxis and treatment

A specific sub-set of passengers, who find themselves at a significantly higher risk for the development of acute, air-travel related VTE, will require pharmacological intervention in the form of anticoagulant prophylaxis.22,25
Anticoagulants are most commonly used to treat DVT and PE. The most frequently used injectable drugs are unfractionated heparin, the newer forms of low molecular weight heparin such as enoxaparin and dalteparin, and fondaparinux (Factor Xa inhibitor). Oral anticoagulants include warfarin (vitamin K antagonist), dabigatran and rivaroxaban. Warfarin is known for its long list of potential drug interactions and the variation in individual responses to this drug may be substantial. Careful monitoring and good compliance are essential to the success of anticoagulant therapy with warfarin.

**Conclusion**

Travelling has an impact on public health, given the millions of travellers across the globe, and risks associated with travelling. Most travel-related diseases can be prevented either through immunisation, chemoprophylaxis or behaviour change. Individual travellers are therefore strongly encouraged to consult a suitable travel clinic and healthcare professional, well in advance of undertaking their trip. An individual pre-travel risk assessment and guidance on suitable or required prophylactic measures, is essential for minimising travel-related risks. The traveller’s medical history, current illnesses and prescribed medication may significantly influence his/her prevention strategies, precautionary measures and/or travel plans.

**References**